drugset / Trial / NCT05192369

A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers

NCT05192369

Phase 1 Completed 48 enrolled Concert Pharmaceuticals
RandomizedCrossoverSingle-blindOther

Summary

This is a four-arm, randomized, crossover, placebo and active controlled study to evaluate of the effect of therapeutic and supratherapeutic doses of CTP-543 on the QT/QTc intervals in healthy volunteers

Timeline

Start
2022-01-04
Primary completion
2022-01-28
Completion
2022-01-28

Drugs

EvaluationDrugModalityDoseRoute
Subject CTP-543 Unknown 12 mg Oral
Subject CTP-543 Unknown 48 mg Oral
Comparator Moxifloxacin Small molecule 400 mg Oral

Indications

No indication recorded.